BioMimetic Therapeutics to Report 2008 First Quarter Financial Results on May 8

Business Wire,  May 7, 2008  

• E-mail
• Print
• Link

FRANKLIN, Tenn. -- BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three months ended March 31, 2008 on Thursday, May 8, 2008 after the close of the market, and will host a conference call and audio webcast at 8:30 EDT the following morning, May 9, 2008. Dr. Samuel E. Lynch, president and CEO, and members of the Company's management team will host the call to discuss the Company's first quarter financial results and product development programs and business activities.

A live webcast of the conference call will be available on the Investor Relations section of BioMimetic's website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.

The conference call may be accessed on May 9, 2008 by dialing 888.713.4209 (passcode: 30353831). The international dial in number is 617.213.4863, and the same passcode applies. Participants may pre-register for the earnings conference call at www.theconferencingservice.com/prereg/key.process?key=PHRKHQUE4. By pre-registering for the call, participants will avoid hold times and will no longer be required to speak to the operator to provide contact information.

About BioMimetic Therapeutics

BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA in 2005 for its first product, GEM 21S, for regeneration of bone and periodontal tissue loss resulting from periodontal disease. Currently, the Company has clinical trials ongoing with its product candidates GEM OS1 and GEM OS2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's product and lead product candidates all combine recombinant human platelet derived growth factor (rhPDGF-BB) with tissue specific scaffolds to actively stimulate tissue healing and regeneration.

GEM 21S[R] is a registered trademark of Luitpold Pharmaceuticals, Inc., who owns and markets that product through its Osteohealth Company division.

For further information, visit www.biomimetics.com or contact Kearstin Patterson, associate director of corporate communications, at 615-236-4419.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning